Pharmaceutical Companies Buy Rivals’ Drugs, Then Jack Up the Prices

On Feb. 10, reports The Wall Street Journal, Valeant Pharmaceuticals International Inc. bought the rights to a pair of life-saving heart drugs. The same day, their list prices rose by 525% and 212%. Neither of the drugs, Nitropress or Isuprel, was improved as a result of costly investment in lab work and human testing, Valeant said. Nor was manufacture of the medicines shifted to an expensive new plant. The big change: the drugs’ ownership.

October 27, 2016 NRA Top Trump Funder National Rifle Association committees making independent campaign expenditures to oppose Democratic presidential nominee Hillary Clinton have spent more than $14 million on the race, surpassing the spending of the most active pro-Trump Super PAC. Acc... Read More >